
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
The positive outlook for uniQure NV is supported by significant advancements in its gene therapy pipeline, particularly with AMT-130 for Huntington's disease and AMT-191 for Fabry disease, which demonstrates strong biological proof-of-concept and moves towards dose optimization. The company has shown strategic financial management, reflected in the increase in SG&A expenses, indicating active investment in growth, while also maintaining a balance sheet that allows for strategic flexibility. Additionally, the collaborations and ongoing clinical trials provide a diversified platform that enhances resilience and reduces risks associated with regulatory changes, reinforcing investor confidence in uniQure's innovative therapies and potential future success.
Bears say
uniQure NV faces significant financial challenges as it remains a clinical stage company with no revenue-generating products, resulting in ongoing losses since its inception. The company is also threatened by intense market competition from both existing and emerging therapies that target similar indications, which can adversely affect its market penetration and pricing strategies. Additionally, potential delays in clinical development, regulatory approvals, or commercialization timelines could lead to prolonged development periods and increased operational costs, further straining the company’s financial resources.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares